Bio-Path stock has taken a beating in the past five years. Investors obviously aren’t happy about this, and the way that management and the board of directors has handled it has been clumsy.
Like all developmental drug companies, Bio-Path is betting on the success of its drug candidates. Drugs that are in trials often fail, so investors need to gamble that one or more of its treatments...
What is it like to have a stock plunge 90% in less than a year and wipe out a huge amount of shareholder value? That's what happened to Bio-Path.
Bio-Path shares are on a rampage, with its second day of more than doubling. Shares actually were halted at multiple points during the day for volatility spikes. This is all coming after the firm...
Bio-Path shares made an incredible run on Wednesday after the company announced interim results from its mid-stage leukemia trial.
The top analyst upgrades, downgrades and initiations seen Monday morning include Arcelor Mittal, Citigroup, 3M, NetApp and Union Pacific.
Source: ThinkstockStocks hit all-time highs yet again this past week. It is amazing that the investment community keeps hearing that the bull market has migrated to a stock picker’s market from a...
Source: ThinkstockEarnings season is winding down and the markets remain choppy. Investors are wary, but they want upside and they keep hearing that this is now a stock picker’s market. 24/7 Wall...